A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00445094

Enrollment

120

Registered

2007-03-08

Start date

2006-11-30

Completion date

2007-01-31

Last updated

2017-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Pneumonia

Brief summary

The primary objective of this study is a comparison between MK0787B and standard therapy.

Interventions

DRUGMK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days

DRUGComparator: amikacin / Duration of Treatment: 3 Days

DRUGComparator: tazocin / Duration of Treatment: 3 Days

DRUGComparator: vancomycin / Duration of Treatment: 3 Days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Greater than 18 years of age * Patient is diagnosed with nosocomial pneumonia

Exclusion criteria

* Immunological deficient patients * Pregnant women and nursing mothers * A fungus is identified before the study enrollment * Received vancomycin or imipenem for more than 5 days before icu admission

Design outcomes

Primary

Measure	Time frame
A 30-day-survival rate in the intensive care unit evaluated by Acute Physiology and Chronic Health (APACH II) Disease Classification System II score	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026